Anavex stockholders elect six directors at 2026 annual meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Wall St subdued in choppy trade after big bank earnings, chips slide
- Oil prices ease as US-Russia diesel deal hopes offset Middle East attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- CoreWeave stock drops on insider selling notice
- Sysco calls on Teamsters to end LA strike after economic deal reached
Anavex Stockholders Elect All of the Company’s Director Nominees at 2026 Annual Meeting
September 24, 2026 10:00 AM EDTNEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with high unmet medical needs, today announced that, based on the preliminary vote count provided by its proxy solicitor following the Companys 2026 Annual Meeting of Stockholders (Annual Meeting), Anavex stockholders have voted to elect all six of its director nominees Dr. Jiong Ma, Dr. Peter Donhauser, Dr. Axel Paeger, Mr. Gautam Patel, Dr. Adrian Senderowicz and Dr. Claus van der Velden.
Dr. Jiong Ma, Independent Chair of the Board, stated, On behalf of the... More



